Drupal.behaviors.print = function(context) {window.print();window.close();}>
Dako, Genentech Partner on Regulatory Submission of CDx for Second Breast Cancer Drug
May 01, 2012
Dako, Genentech Partner on Regulatory Submission of CDx for Second Breast Cancer Drug
By
a GenomeWeb staff reporter
Full-text access for registered users only.
Existing users
login here
.
New to GenomeWeb?
Register here
quickly for free access.
Related Stories
Dako, Genentech Partner on Companion Dx FDA Submission for Pertuzumab
December 9, 2011 / GenomeWeb Daily News
FDA Approves Dako Assays as CDx for Genentech Breast Cancer Drug
March 5, 2013 / GenomeWeb Daily News
FDA Approves Dako Assays as CDx for Genentech's Breast Cancer Treatment
June 12, 2012 / GenomeWeb Daily News
FDA Clears Dako's Companion Dx for Herceptin
December 13, 2011 / GenomeWeb Daily News
FDA Approves HER2 Test for Breast Cancer
June 14, 2011 / GenomeWeb Daily News